Trial Profile
Association between adherence to Palivizumab and the incidence of Respiratory Syncytial Virus -associated outcomes in the Canadian Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2017
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- 02 Nov 2017 New trial record